Our extensive experience in health technology assessment (HTA) through providing strategic advice and guiding evidence generation to support submissions to UK HTA bodies, enables us to provide you with a tailored solution to reimbursement and patient access.
The 2023 EB Insights Study: the impact of epidermolysis bullosa on the health related quality of life of patients and their carers. Poster PCR97. Presented at: ISPOR Europe 2024; 17-20 November 2024; Barcelona, Spain.